Synairgen Share Discussion Threads

[lithological heterogeneities] 21/4/2020 19:42

Clearly SNG are VERY busy !

[lithological heterogeneities] 21/4/2020 19:40

"Sharesting" received email reply tonight from Richard Marsden,SNG CEO:"Sharesting" asked if he could update us in marketing or RNS.Richard Marsden reply:"I am buried in work, very operational at the moment, things you'd most want me/us to be concentrating on."

[141jaffa] 21/4/2020 19:38

<< All eligible patients are randomly allocated between several
treatment arms, each to be given in addition to the usual standard of care in the
participating hospital: No additional treatment vs Lopinavir-Ritonavir vs Low-dose
Corticosteroids vs Hydroxychloroquine vs Azithromycin >>

OK,thanks - I had ignored normal hospital care as a placebo, more of a benchmark, but I suppose it is of course here .

[royalalbert] 21/4/2020 19:22

Don't know if this one has been posted.

[nobbygnome] 21/4/2020 19:22

There is a placebo group in the Recovery trial. The spilt is 2.1.1.1.1 so twice as many in the placebo group as anything else. Since it is open label it is really difficult to see how on earth that works!

[141jaffa] 21/4/2020 19:21

I couldnt see a placebo in the Recovery Trial, so the TV interview tonight sounds like it could be the SNG one as a placebo was mentioned I believe - Ive not watched it yet but apparently the interviewee sounded bullish ??

[likya123] 21/4/2020 19:15

This is global randomised trial..

[slinkyj] 21/4/2020 19:14

Yes , it says so in the wording

[141jaffa] 21/4/2020 19:14

apologies - it states it !!

[nobbygnome] 21/4/2020 19:13

>> talk

As it kept on going up I kept on increasing my short. Reaping the dividends now. A lot further to go IMHO so I will be holding on to most of it. Bought back about 20% so far with a lovely profit....again!

[141jaffa] 21/4/2020 19:13

yes, I think ours is the SARS 2 one

[likya123] 21/4/2020 19:10

This is ours...

[talk2dubya] 21/4/2020 19:02

Luke - lets put it this way it’s 55 and unders who can volunteer for the vaccine !

[lukead] 21/4/2020 19:00

Who has said “keeping the elderly locked up for 18 months” is this just something from a paper. And what age is classified as elderly, 65, 70 ?

[talk2dubya] 21/4/2020 18:59

Luke - Synairgen has had a lot of PR. It has also had a lot of shares dumped in to the market, that is the issue with the share price

Progress seems to be going well based on last update, let’s wait and see.

[lukead] 21/4/2020 18:56

If you could buy shares for this vaccine from Oxford, with all this publicity from the right people, to quote a phrase “the share would be hitting the roof in anticipation”
Whereas the PR for SGN is ?

[talk2dubya] 21/4/2020 18:54

Sorry wrong link:

Interesting first submission and first posting dates.

hxxps://clinicaltrials.gov/ct2/show/NCT04324606

[dave444] 21/4/2020 18:54

The reason for that is they state we cannot fully get back to normal until an effective vaccine is found so not surprising they are wishing it to be successful!They are talking of keeping the elderly locked up for as much as 18 months until it is over

[talk2dubya] 21/4/2020 18:52

hxxps://clinicaltrials.gov/ct2/show/NCT04324606


Whilst it is hopefully good news, its a six month study, even if they do manage to find a vaccine it will not deal with the issues currently faced.

Interesting date that they first started the trial per the attached.

[lukead] 21/4/2020 18:50

Never occurred to me and that is speculation on your part.
But this vaccine is getting a lot of play. The media and the Gov seem to think that is the one to go for, treatments hardly get a mention, which is unlucky.

[talk2dubya] 21/4/2020 18:44

How do you know there is not a link between the two ?

[lukead] 21/4/2020 18:40

They are talking about this vaccine as if it’s a no brainer with lots of testing to do. Now why no talk of SGN, testing just the same, shame.

[pdt] 21/4/2020 18:29

Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19



From the Absract conclusion;

In this study, we found no evidence that use of hydroxychloroquine, either with or without azithromycin, reduced the risk of mechanical ventilation in patients hospitalized with Covid-19. An association of increased overall mortality was identified in patients treated with hydroxychloroquine alone. These findings highlight the importance of awaiting the results of ongoing prospective, randomized, controlled studies before widespread adoption of these drugs.